Want to see SE:NEEMS.B full AI Analyst Report?
Top Page
Scandinavian ChemoTech AB Class B
(NEEMS.B)
Select Model
Select Model
Rating:47Neutral
Price Target:
kr2.50
▼(-47.81% Downside)
Action:Reiterated
Date:07/13/26
The score is primarily held back by weak financial performance—ongoing net losses and negative free cash flow despite strong revenue growth and improved gross margin. Technical signals are broadly neutral with only a slight positive MACD, offering limited support. Valuation is also constrained because the company is loss-making (negative P/E) and has no dividend yield provided.
Positive Factors
Strong Revenue Growth
Rapid revenue expansion indicates growing commercialization of the IQWave/TSE platform and increasing customer adoption. If this trajectory persists, a larger installed base could support recurring consumables, service income, and operating leverage as the company scales beyond its current base.
Negative Factors
Persistent Net Losses
Large ongoing losses show that current revenue and gross profit are not yet sufficient to cover operating expenses. Unless the company converts growth into operating profitability, earnings quality will remain weak and the business may need additional funding to sustain commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Rapid revenue expansion indicates growing commercialization of the IQWave/TSE platform and increasing customer adoption. If this trajectory persists, a larger installed base could support recurring consumables, service income, and operating leverage as the company scales beyond its current base.
Read all positive factors
Scandinavian ChemoTech AB Class B (NEEMS.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr73.93M
Dividend YieldN/A
Average Volume (3M)13.97K
Price to Earnings (P/E)―
Beta (1Y)-0.65
Revenue Growth22.42%
EPS Growth30.55%
CountrySE
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.25
Shares Outstanding23,802,313
10 Day Avg. Volume9,508
30 Day Avg. Volume13,974
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)37.86
Price to Sales (P/S)9.82
P/FCF Ratio-28.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr19.10M
Scandinavian ChemoTech AB Class B Business Overview & Revenue Model
Company Description
Scandinavian ChemoTech AB (publ), a medical technology company, engages in the radiation physics, surgical oncology, and clinical development in Sweden and internationally. It operates in two divisions, Human Care and Animal Care. The company offe...
How the Company Makes Money
ChemoTech primarily makes money by commercializing its electroporation-based oncology treatment platform (IQWave/TSE) to healthcare providers. Revenue is generated mainly through (1) sales of IQWave systems (capital equipment) to clinics and hospi...
Scandinavian ChemoTech AB Class B Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
52
Neutral
Cash Flow
24
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Scandinavian ChemoTech AB Class B Technical Analysis
Negative
4.79
Price Trends
3.31
Negative
3.51
Negative
3.68
Negative
Market Momentum
-0.11
Positive
33.67
Neutral
45.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NEEMS.B, the sentiment is Negative. The current price of 4.79 is above the 20-day moving average (MA) of 3.06, above the 50-day MA of 3.31, and above the 200-day MA of 3.68, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 33.67 is Neutral, neither overbought nor oversold. The STOCH value of 45.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:NEEMS.B.
Scandinavian ChemoTech AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr487.76M | 2.49 | 63.09% | ― | ― | ― | |
53 Neutral | kr665.87M | -2.16 | ― | ― | 87.23% | 35.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr233.64M | -3.63 | -54.41% | ― | ― | 32.79% | |
48 Neutral | kr188.86M | -7.63 | -56.09% | ― | ― | 14.10% | |
48 Neutral | kr463.07M | -4.02 | -18.05% | ― | ― | 15.97% | |
47 Neutral | kr73.93M | -14.45 | -190.99% | ― | 22.42% | 30.55% |
* Healthcare Sector Average
SE:NEEMS.B
Scandinavian ChemoTech AB Class B
2.75
-1.62
-37.07%
SE:ONCO
Oncopeptides AB
1.69
-3.33
-66.37%
SE:ISOFOL
Isofol Medical AB
0.74
-0.07
-8.64%
SE:ELIC
Elicera Therapeutics AB
2.70
-3.83
-58.64%
SE:IMMU
Immunicum AB
7.19
-0.56
-7.23%
SE:CANTA
Cantargia AB
1.70
-0.95
-35.88%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.